Effect of elevated fasting blood glucose level on the 1‐year mortality and sequelae in hospitalized COVID‐19 patients: A bidirectional cohort study
To observe the predictive effect of fasting blood glucose (FBG) level on the prognosis, clinical sequelae, and pulmonary absorption in hospitalized coronavirus disease 2019 (COVID‐19) patients with and without a history of diabetes, respectively, and to evaluate the correlation between the dynamic c...
Saved in:
| Published in | Journal of medical virology Vol. 94; no. 7; pp. 3240 - 3250 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.07.2022
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | To observe the predictive effect of fasting blood glucose (FBG) level on the prognosis, clinical sequelae, and pulmonary absorption in hospitalized coronavirus disease 2019 (COVID‐19) patients with and without a history of diabetes, respectively, and to evaluate the correlation between the dynamic changes of FBG and poor prognosis. In this bidirectional cohort study, we enrolled 2545 hospitalized COVID‐19 patients (439 diabetics and 2106 without a diabetic history) and followed up for 1 year. The patients were divided according to the level of admission FBG. The dynamic changes of FBG were compared between the survival and the death cases. The prediction effect of FBG on 1‐year mortality and sequelae was analyzed. The 1‐year all cause mortality rate and in‐hospital mortality rate of COVID‐19 patients were J‐curve correlated with FBG (p < 0.001 for both in the nondiabetic history group, p = 0.004 and p = 0.01 in the diabetic history group). FBG ≥ 7.0 mmol/L had a higher risk of developing sequelae (p = 0.025) and have slower recovery of abnormal lung scans (p < 0.001) in patients who denied a history of diabetes. Multivariable Cox regression analysis showed that FBG ≥ 7.0 mmol/L was an independent risk factor for the mortality of COVID‐19 regardless of the presence or deny a history of diabetes (hazard atio [HR] = 10.63, 95% confidence interval [CI]: 7.15−15.83, p < 0.001; HR = 3.9, 95% CI: 1.56−9.77, p = 0.004, respectively). Our study shows that FBG ≥ 7.0 mmol/L can be a predictive factor of 1‐year all‐cause mortality in COVID‐19 patients, independent of diabetes history. FBG ≥ 7.0 mmol/L has an advantage in predicting the severity, clinical sequelae, and pulmonary absorption in COVID‐19 patients without a history of diabetes. Early detection, timely treatment, and strict control of blood glucose when finding hyperglycemia in COVID‐19 patients (with or without diabetes) are critical for their prognosis. |
|---|---|
| AbstractList | To observe the predictive effect of fasting blood glucose (FBG) level on the prognosis, clinical sequelae, and pulmonary absorption in hospitalized coronavirus disease 2019 (COVID‐19) patients with and without a history of diabetes, respectively, and to evaluate the correlation between the dynamic changes of FBG and poor prognosis. In this bidirectional cohort study, we enrolled 2545 hospitalized COVID‐19 patients (439 diabetics and 2106 without a diabetic history) and followed up for 1 year. The patients were divided according to the level of admission FBG. The dynamic changes of FBG were compared between the survival and the death cases. The prediction effect of FBG on 1‐year mortality and sequelae was analyzed. The 1‐year all cause mortality rate and in‐hospital mortality rate of COVID‐19 patients were J‐curve correlated with FBG (p < 0.001 for both in the nondiabetic history group, p = 0.004 and p = 0.01 in the diabetic history group). FBG ≥ 7.0 mmol/L had a higher risk of developing sequelae (p = 0.025) and have slower recovery of abnormal lung scans (p < 0.001) in patients who denied a history of diabetes. Multivariable Cox regression analysis showed that FBG ≥ 7.0 mmol/L was an independent risk factor for the mortality of COVID‐19 regardless of the presence or deny a history of diabetes (hazard atio [HR] = 10.63, 95% confidence interval [CI]: 7.15−15.83, p < 0.001; HR = 3.9, 95% CI: 1.56−9.77, p = 0.004, respectively). Our study shows that FBG ≥ 7.0 mmol/L can be a predictive factor of 1‐year all‐cause mortality in COVID‐19 patients, independent of diabetes history. FBG ≥ 7.0 mmol/L has an advantage in predicting the severity, clinical sequelae, and pulmonary absorption in COVID‐19 patients without a history of diabetes. Early detection, timely treatment, and strict control of blood glucose when finding hyperglycemia in COVID‐19 patients (with or without diabetes) are critical for their prognosis. To observe the predictive effect of fasting blood glucose (FBG) level on the prognosis, clinical sequelae, and pulmonary absorption in hospitalized coronavirus disease 2019 (COVID‐19) patients with and without a history of diabetes, respectively, and to evaluate the correlation between the dynamic changes of FBG and poor prognosis. In this bidirectional cohort study, we enrolled 2545 hospitalized COVID‐19 patients (439 diabetics and 2106 without a diabetic history) and followed up for 1 year. The patients were divided according to the level of admission FBG. The dynamic changes of FBG were compared between the survival and the death cases. The prediction effect of FBG on 1‐year mortality and sequelae was analyzed. The 1‐year all cause mortality rate and in‐hospital mortality rate of COVID‐19 patients were J‐curve correlated with FBG ( p < 0.001 for both in the nondiabetic history group, p = 0.004 and p = 0.01 in the diabetic history group). FBG ≥ 7.0 mmol/L had a higher risk of developing sequelae ( p = 0.025) and have slower recovery of abnormal lung scans ( p < 0.001) in patients who denied a history of diabetes. Multivariable Cox regression analysis showed that FBG ≥ 7.0 mmol/L was an independent risk factor for the mortality of COVID‐19 regardless of the presence or deny a history of diabetes (hazard atio [HR] = 10.63, 95% confidence interval [CI]: 7.15−15.83, p < 0.001; HR = 3.9, 95% CI: 1.56−9.77, p = 0.004, respectively). Our study shows that FBG ≥ 7.0 mmol/L can be a predictive factor of 1‐year all‐cause mortality in COVID‐19 patients, independent of diabetes history. FBG ≥ 7.0 mmol/L has an advantage in predicting the severity, clinical sequelae, and pulmonary absorption in COVID‐19 patients without a history of diabetes. Early detection, timely treatment, and strict control of blood glucose when finding hyperglycemia in COVID‐19 patients (with or without diabetes) are critical for their prognosis. To observe the predictive effect of fasting blood glucose (FBG) level on the prognosis, clinical sequelae, and pulmonary absorption in hospitalized coronavirus disease 2019 (COVID-19) patients with and without a history of diabetes, respectively, and to evaluate the correlation between the dynamic changes of FBG and poor prognosis. In this bidirectional cohort study, we enrolled 2545 hospitalized COVID-19 patients (439 diabetics and 2106 without a diabetic history) and followed up for 1 year. The patients were divided according to the level of admission FBG. The dynamic changes of FBG were compared between the survival and the death cases. The prediction effect of FBG on 1-year mortality and sequelae was analyzed. The 1-year all cause mortality rate and in-hospital mortality rate of COVID-19 patients were J-curve correlated with FBG (p < 0.001 for both in the nondiabetic history group, p = 0.004 and p = 0.01 in the diabetic history group). FBG ≥ 7.0 mmol/L had a higher risk of developing sequelae (p = 0.025) and have slower recovery of abnormal lung scans (p < 0.001) in patients who denied a history of diabetes. Multivariable Cox regression analysis showed that FBG ≥ 7.0 mmol/L was an independent risk factor for the mortality of COVID-19 regardless of the presence or deny a history of diabetes (hazard atio [HR] = 10.63, 95% confidence interval [CI]: 7.15-15.83, p < 0.001; HR = 3.9, 95% CI: 1.56-9.77, p = 0.004, respectively). Our study shows that FBG ≥ 7.0 mmol/L can be a predictive factor of 1-year all-cause mortality in COVID-19 patients, independent of diabetes history. FBG ≥ 7.0 mmol/L has an advantage in predicting the severity, clinical sequelae, and pulmonary absorption in COVID-19 patients without a history of diabetes. Early detection, timely treatment, and strict control of blood glucose when finding hyperglycemia in COVID-19 patients (with or without diabetes) are critical for their prognosis. To observe the predictive effect of fasting blood glucose (FBG) level on the prognosis, clinical sequelae, and pulmonary absorption in hospitalized coronavirus disease 2019 (COVID‐19) patients with and without a history of diabetes, respectively, and to evaluate the correlation between the dynamic changes of FBG and poor prognosis. In this bidirectional cohort study, we enrolled 2545 hospitalized COVID‐19 patients (439 diabetics and 2106 without a diabetic history) and followed up for 1 year. The patients were divided according to the level of admission FBG. The dynamic changes of FBG were compared between the survival and the death cases. The prediction effect of FBG on 1‐year mortality and sequelae was analyzed. The 1‐year all cause mortality rate and in‐hospital mortality rate of COVID‐19 patients were J‐curve correlated with FBG (p < 0.001 for both in the nondiabetic history group, p = 0.004 and p = 0.01 in the diabetic history group). FBG ≥ 7.0 mmol/L had a higher risk of developing sequelae (p = 0.025) and have slower recovery of abnormal lung scans (p < 0.001) in patients who denied a history of diabetes. Multivariable Cox regression analysis showed that FBG ≥ 7.0 mmol/L was an independent risk factor for the mortality of COVID‐19 regardless of the presence or deny a history of diabetes (hazard atio [HR] = 10.63, 95% confidence interval [CI]: 7.15−15.83, p < 0.001; HR = 3.9, 95% CI: 1.56−9.77, p = 0.004, respectively). Our study shows that FBG ≥ 7.0 mmol/L can be a predictive factor of 1‐year all‐cause mortality in COVID‐19 patients, independent of diabetes history. FBG ≥ 7.0 mmol/L has an advantage in predicting the severity, clinical sequelae, and pulmonary absorption in COVID‐19 patients without a history of diabetes. Early detection, timely treatment, and strict control of blood glucose when finding hyperglycemia in COVID‐19 patients (with or without diabetes) are critical for their prognosis. To observe the predictive effect of fasting blood glucose (FBG) level on the prognosis, clinical sequelae, and pulmonary absorption in hospitalized coronavirus disease 2019 (COVID-19) patients with and without a history of diabetes, respectively, and to evaluate the correlation between the dynamic changes of FBG and poor prognosis. In this bidirectional cohort study, we enrolled 2545 hospitalized COVID-19 patients (439 diabetics and 2106 without a diabetic history) and followed up for 1 year. The patients were divided according to the level of admission FBG. The dynamic changes of FBG were compared between the survival and the death cases. The prediction effect of FBG on 1-year mortality and sequelae was analyzed. The 1-year all cause mortality rate and in-hospital mortality rate of COVID-19 patients were J-curve correlated with FBG (p < 0.001 for both in the nondiabetic history group, p = 0.004 and p = 0.01 in the diabetic history group). FBG ≥ 7.0 mmol/L had a higher risk of developing sequelae (p = 0.025) and have slower recovery of abnormal lung scans (p < 0.001) in patients who denied a history of diabetes. Multivariable Cox regression analysis showed that FBG ≥ 7.0 mmol/L was an independent risk factor for the mortality of COVID-19 regardless of the presence or deny a history of diabetes (hazard atio [HR] = 10.63, 95% confidence interval [CI]: 7.15-15.83, p < 0.001; HR = 3.9, 95% CI: 1.56-9.77, p = 0.004, respectively). Our study shows that FBG ≥ 7.0 mmol/L can be a predictive factor of 1-year all-cause mortality in COVID-19 patients, independent of diabetes history. FBG ≥ 7.0 mmol/L has an advantage in predicting the severity, clinical sequelae, and pulmonary absorption in COVID-19 patients without a history of diabetes. Early detection, timely treatment, and strict control of blood glucose when finding hyperglycemia in COVID-19 patients (with or without diabetes) are critical for their prognosis.To observe the predictive effect of fasting blood glucose (FBG) level on the prognosis, clinical sequelae, and pulmonary absorption in hospitalized coronavirus disease 2019 (COVID-19) patients with and without a history of diabetes, respectively, and to evaluate the correlation between the dynamic changes of FBG and poor prognosis. In this bidirectional cohort study, we enrolled 2545 hospitalized COVID-19 patients (439 diabetics and 2106 without a diabetic history) and followed up for 1 year. The patients were divided according to the level of admission FBG. The dynamic changes of FBG were compared between the survival and the death cases. The prediction effect of FBG on 1-year mortality and sequelae was analyzed. The 1-year all cause mortality rate and in-hospital mortality rate of COVID-19 patients were J-curve correlated with FBG (p < 0.001 for both in the nondiabetic history group, p = 0.004 and p = 0.01 in the diabetic history group). FBG ≥ 7.0 mmol/L had a higher risk of developing sequelae (p = 0.025) and have slower recovery of abnormal lung scans (p < 0.001) in patients who denied a history of diabetes. Multivariable Cox regression analysis showed that FBG ≥ 7.0 mmol/L was an independent risk factor for the mortality of COVID-19 regardless of the presence or deny a history of diabetes (hazard atio [HR] = 10.63, 95% confidence interval [CI]: 7.15-15.83, p < 0.001; HR = 3.9, 95% CI: 1.56-9.77, p = 0.004, respectively). Our study shows that FBG ≥ 7.0 mmol/L can be a predictive factor of 1-year all-cause mortality in COVID-19 patients, independent of diabetes history. FBG ≥ 7.0 mmol/L has an advantage in predicting the severity, clinical sequelae, and pulmonary absorption in COVID-19 patients without a history of diabetes. Early detection, timely treatment, and strict control of blood glucose when finding hyperglycemia in COVID-19 patients (with or without diabetes) are critical for their prognosis. |
| Author | Chai, Chen Chen, Kui Wei, Dunshuang Sun, Qi Wang, Wendan Li, Shoupeng Peng, Cao Tang, Zehai Cheng, Gang Wang, Hongxiang |
| AuthorAffiliation | 1 Department of Emergency Medicine, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China 2 Department of Emergency Medicine Zhongnan Hospital of Wuhan University Wuhan China 3 Department of Emergency Medicine, Affiliated Dongfeng Hospital Hubei University of Medicine Shiyan Hubei China 4 Department of Emergency Medicine, Huanan Hospital Shenzhen University Shenzhen China 5 Computer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China 7 Department of Emergency Medicine The Third People's Hospital of Hubei Province Wuhan China 6 Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology Wuhan China |
| AuthorAffiliation_xml | – name: 7 Department of Emergency Medicine The Third People's Hospital of Hubei Province Wuhan China – name: 1 Department of Emergency Medicine, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China – name: 5 Computer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China – name: 3 Department of Emergency Medicine, Affiliated Dongfeng Hospital Hubei University of Medicine Shiyan Hubei China – name: 2 Department of Emergency Medicine Zhongnan Hospital of Wuhan University Wuhan China – name: 4 Department of Emergency Medicine, Huanan Hospital Shenzhen University Shenzhen China – name: 6 Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology Wuhan China |
| Author_xml | – sequence: 1 givenname: Chen orcidid: 0000-0002-6009-3427 surname: Chai fullname: Chai, Chen organization: Zhongnan Hospital of Wuhan University – sequence: 2 givenname: Kui orcidid: 0000-0002-3910-1402 surname: Chen fullname: Chen, Kui organization: Hubei University of Medicine – sequence: 3 givenname: Shoupeng orcidid: 0000-0002-5009-8013 surname: Li fullname: Li, Shoupeng organization: Shenzhen University – sequence: 4 givenname: Gang surname: Cheng fullname: Cheng, Gang organization: Huazhong University of Science and Technology – sequence: 5 givenname: Wendan orcidid: 0000-0001-5659-0810 surname: Wang fullname: Wang, Wendan organization: Huazhong University of Science and Technology – sequence: 6 givenname: Hongxiang orcidid: 0000-0002-2499-3604 surname: Wang fullname: Wang, Hongxiang organization: Huazhong University of Science and Technology – sequence: 7 givenname: Dunshuang surname: Wei fullname: Wei, Dunshuang organization: The Third People's Hospital of Hubei Province – sequence: 8 givenname: Cao orcidid: 0000-0002-9552-6392 surname: Peng fullname: Peng, Cao organization: Huazhong University of Science and Technology – sequence: 9 givenname: Qi orcidid: 0000-0002-6392-3529 surname: Sun fullname: Sun, Qi organization: Huazhong University of Science and Technology – sequence: 10 givenname: Zehai orcidid: 0000-0002-2823-1009 surname: Tang fullname: Tang, Zehai email: tangzehai@hust.edu.cn organization: Huazhong University of Science and Technology |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35357022$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks1u1DAUhS1URKeFBS-ALLGBRVr_xE7MAqkaChQVdQPdWo5zM-ORJx7iZFC66iOw4_14EhxmiqCClRf3nM_n_hyhgza0gNBTSk4oIex0td6esKLgxQM0o0TJTJGCHqAZobnMpKTiEB3FuCKElIqxR-iQCy4KwtgMfT9vGrA9Dg0GD1vTQ40bE3vXLnDlQ6jxwg82RMCpCh6HFvdLwPTH7bcRTIfXoeuNd_2ITVvjCF8G8Aawa_EyxI2bajcJOb-6vniTPFThjekdtH18hc9w5WrXpe9daI3HNiwTDcd-qMfH6GFjfIQn-_cYfX57_mn-Pru8encxP7vMbJ7zIquAScspN1xxCqTMhbFKWUssZZXkNWeVELLIieSlabioS26pUg0QwYRRlB-j1zvuZqjWUNuUrDNebzq3Nt2og3H670rrlnoRtlqRspS0TIAXe0AXUvOx12sXLXhvWghD1EzmohSKcZKkz-9JV2HoUueTSgohSsKnRM_-TPQ7yt3OkuB0J7BdiLGDRts052mGKaDzmhI9XYVOV6F_XUVyvLznuIP-S7unf3Uexv8L9YeP1zvHT74ZybQ |
| CitedBy_id | crossref_primary_10_1186_s12879_024_09084_8 crossref_primary_10_1002_jmv_28100 crossref_primary_10_1016_j_sapharm_2024_02_007 crossref_primary_10_4103_ijciis_ijciis_41_23 crossref_primary_10_1080_17446651_2025_2469627 crossref_primary_10_3389_fendo_2022_974540 crossref_primary_10_3390_ijerph192013230 crossref_primary_10_4274_haseki_galenos_2022_8501 crossref_primary_10_1007_s00125_023_05928_1 crossref_primary_10_3390_biomedicines11030971 crossref_primary_10_1016_j_diabres_2022_110202 |
| Cites_doi | 10.1002/iub.2536 10.1007/s00592-009-0109-4 10.1016/j.jcv.2020.104354 10.1016/j.diabres.2020.108437 10.1007/s00592-021-01751-5 10.1111/dme.14300 10.1007/s00125-020-05284-4 10.2337/diacare.28.4.810 10.2337/dc16-1170 10.1016/S0140-6736(10)60484-9 10.2337/db20-0669 10.3389/fendo.2020.00525 10.1007/s00134-004-2167-y 10.1002/jmv.26608 10.1016/S2213-8587(16)30321-7 10.2337/dc20-1380 10.1016/j.diabres.2020.108561 10.1152/ajpendo.00124.2020 10.1007/s00125-020-05209-1 10.1002/dmrr.3346 10.2337/dc20-0723 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors. published by Wiley Periodicals LLC. 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. 2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2022 The Authors. published by Wiley Periodicals LLC. – notice: 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. – notice: 2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION NPM 7QL 7TK 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 5PM |
| DOI | 10.1002/jmv.27737 |
| DatabaseName | Wiley Online Library Open Access CrossRef PubMed Bacteriology Abstracts (Microbiology B) Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Genetics Abstracts Virology and AIDS Abstracts Technology Research Database Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | PubMed Genetics Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | CHAI et al |
| EISSN | 1096-9071 |
| EndPage | 3250 |
| ExternalDocumentID | PMC9088618 35357022 10_1002_jmv_27737 JMV27737 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Natural Science Foundation of Hubei Province funderid: 2020CFB804 – fundername: Natural Science Foundation of Hubei Province grantid: 2020CFB804 – fundername: ; grantid: 2020CFB804 |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 31~ 33P 3O- 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS ECGQY EJD ELTNK EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E VH1 W8V W99 WBKPD WHG WIB WIH WIJ WIK WJL WNSPC WOHZO WQJ WRC WUP WXI WXSBR WYISQ X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~KM ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION NPM 7QL 7TK 7U9 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY C1K FR3 H94 K9. M7N P64 RC3 7X8 5PM |
| ID | FETCH-LOGICAL-c4437-be26c313a3931e0845ac99cc0c12b63d32b556740638af35d83c199fe0525a913 |
| IEDL.DBID | DR2 |
| ISSN | 0146-6615 1096-9071 |
| IngestDate | Thu Aug 21 18:26:09 EDT 2025 Fri Jul 11 05:59:08 EDT 2025 Sat Jul 26 02:22:21 EDT 2025 Thu Apr 03 07:00:10 EDT 2025 Tue Jul 01 02:24:53 EDT 2025 Thu Apr 24 23:11:25 EDT 2025 Wed Jan 22 16:26:16 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | 1-year mortality fasting blood glucose clinical sequelae coronavirus disease 2019 nondiabetics |
| Language | English |
| License | Attribution 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4437-be26c313a3931e0845ac99cc0c12b63d32b556740638af35d83c199fe0525a913 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-9552-6392 0000-0002-6392-3529 0000-0002-3910-1402 0000-0002-2823-1009 0000-0002-5009-8013 0000-0002-6009-3427 0000-0002-2499-3604 0000-0001-5659-0810 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.27737 |
| PMID | 35357022 |
| PQID | 2665558031 |
| PQPubID | 105515 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9088618 proquest_miscellaneous_2645859230 proquest_journals_2665558031 pubmed_primary_35357022 crossref_citationtrail_10_1002_jmv_27737 crossref_primary_10_1002_jmv_27737 wiley_primary_10_1002_jmv_27737_JMV27737 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | July 2022 |
| PublicationDateYYYYMMDD | 2022-07-01 |
| PublicationDate_xml | – month: 07 year: 2022 text: July 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: London – name: Hoboken |
| PublicationTitle | Journal of medical virology |
| PublicationTitleAlternate | J Med Virol |
| PublicationYear | 2022 |
| Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
| References | 2017; 5 2021; 58 2004; 30 2010; 47 2020; 63 2021 2021; 171 2020; 127 2010; 375 2020; 37 2020; 69 2020; 36 2020; 11 2020; 43 2020; 169 2021; 93 2016; 39 2005; 28 2021; 73 2020; 318 e_1_2_10_12_1 e_1_2_10_23_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_10_1 e_1_2_10_21_1 e_1_2_10_11_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 |
| References_xml | – volume: 47 start-page: 193 issue: 3 year: 2010 end-page: 199 article-title: Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes publication-title: Acta Diabetol – volume: 11 start-page: 525 year: 2020 article-title: Impaired fasting glucose and diabetes are related to higher risks of complications and mortality among patients with coronavirus disease 2019 publication-title: Front Endocrinol (Lausanne) – volume: 37 start-page: 723 issue: 5 year: 2020 end-page: 725 article-title: COVID‐19 and diabetes publication-title: Diabet Med – volume: 43 start-page: 2345 issue: 10 year: 2020 end-page: 2348 article-title: Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID‐19: the Pisa COVID‐19 Study publication-title: Diabetes Care – volume: 63 start-page: 2102 issue: 10 year: 2020 end-page: 2111 article-title: Fasting blood glucose at admission is an independent predictor for 28‐day mortality in patients with COVID‐19 without previous diagnosis of diabetes: a multi‐centre retrospective study publication-title: Diabetologia – volume: 171 year: 2021 article-title: High admission blood glucose independently predicts poor prognosis in COVID‐19 patients: a systematic review and dose‐response meta‐analysis publication-title: Diabetes Res Clin Pract – volume: 36 issue: 8 year: 2020 article-title: The diabetic lung: an easy target for SARS‐CoV‐2? publication-title: Diabetes Metab Res Rev – volume: 375 start-page: 2215 issue: 9733 year: 2010 end-page: 2222 article-title: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta‐analysis of 102 prospective studies publication-title: Lancet – volume: 43 start-page: 1408 issue: 7 year: 2020 end-page: 1415 article-title: Outcomes in patients with hyperglycemia affected by COVID‐19: can we do more on glycemic control? publication-title: Diabetes Care – volume: 69 start-page: 2691 issue: 12 year: 2020 end-page: 2699 article-title: Expression of ACE2, the SARS‐CoV‐2 receptor, in lung tissue of patients with type 2 diabetes publication-title: Diabetes – volume: 127 year: 2020 article-title: Diabetic patients with COVID‐19 infection are at higher risk of ICU admission and poor short‐term outcome publication-title: J Clin Virol – volume: 30 start-page: 748 issue: 5 year: 2004 end-page: 56 article-title: Stress‐hyperglycemia, insulin and immunomodulation in sepsis publication-title: Intensive Care Med – volume: 63 start-page: 2548 issue: 12 year: 2020 end-page: 2558 article-title: Antibody response to multiple antigens of SARS‐CoV‐2 in patients with diabetes: an observational cohort study publication-title: Diabetologia – volume: 318 start-page: E736 issue: 5 year: 2020 end-page: E741 article-title: COVID‐19 pandemic, coronaviruses, and diabetes mellitus publication-title: Am J Physiol‐Endocrinol Metabol – year: 2021 – volume: 93 start-page: 2168 issue: 4 year: 2021 end-page: 2176 article-title: Admission fasting plasma glucose is an independent risk factor for 28‐day mortality in patients with COVID‐19 publication-title: J Med Virol – volume: 169 year: 2020 article-title: Fasting blood glucose level is a predictor of mortality in patients with COVID‐19 independent of diabetes history publication-title: Diabetes Res Clin Pract – volume: 39 start-page: 2051 issue: 11 year: 2016 end-page: 2057 article-title: Hispanics/Latinos with type 2 diabetes have functional and symptomatic pulmonary impairment mirroring kidney microangiopathy: findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) publication-title: Diabetes Care – volume: 28 start-page: 810 issue: 4 year: 2005 end-page: 815 article-title: The relation between hyperglycemia and outcomes in 2471 patients admitted to the hospital with community‐acquired pneumonia publication-title: Diabetes Care – volume: 58 start-page: 1481 issue: 11 year: 2021 end-page: 1490 article-title: Dysglycemia after COVID‐19 pneumonia: a six‐month cohort study publication-title: Acta Diabetol – volume: 5 start-page: 34 issue: 1 year: 2017 end-page: 42 article-title: Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study publication-title: Lancet Diabetes Endocrinol – volume: 73 start-page: 1244 issue: 10 year: 2021 end-page: 1256 article-title: One‐year mortality and consequences of COVID‐19 in cancer patients: a cohort study publication-title: IUBMB Life – ident: e_1_2_10_11_1 doi: 10.1002/iub.2536 – ident: e_1_2_10_12_1 doi: 10.1007/s00592-009-0109-4 – ident: e_1_2_10_19_1 doi: 10.1016/j.jcv.2020.104354 – ident: e_1_2_10_2_1 – ident: e_1_2_10_6_1 doi: 10.1016/j.diabres.2020.108437 – ident: e_1_2_10_10_1 doi: 10.1007/s00592-021-01751-5 – ident: e_1_2_10_20_1 doi: 10.1111/dme.14300 – ident: e_1_2_10_16_1 doi: 10.1007/s00125-020-05284-4 – ident: e_1_2_10_17_1 doi: 10.2337/diacare.28.4.810 – ident: e_1_2_10_15_1 doi: 10.2337/dc16-1170 – ident: e_1_2_10_23_1 doi: 10.1016/S0140-6736(10)60484-9 – ident: e_1_2_10_18_1 doi: 10.2337/db20-0669 – ident: e_1_2_10_3_1 doi: 10.3389/fendo.2020.00525 – ident: e_1_2_10_14_1 doi: 10.1007/s00134-004-2167-y – ident: e_1_2_10_13_1 doi: 10.1002/jmv.26608 – ident: e_1_2_10_9_1 doi: 10.1016/S2213-8587(16)30321-7 – ident: e_1_2_10_4_1 doi: 10.2337/dc20-1380 – ident: e_1_2_10_8_1 doi: 10.1016/j.diabres.2020.108561 – ident: e_1_2_10_21_1 doi: 10.1152/ajpendo.00124.2020 – ident: e_1_2_10_7_1 doi: 10.1007/s00125-020-05209-1 – ident: e_1_2_10_22_1 doi: 10.1002/dmrr.3346 – ident: e_1_2_10_5_1 doi: 10.2337/dc20-0723 |
| SSID | ssj0008922 |
| Score | 2.429721 |
| Snippet | To observe the predictive effect of fasting blood glucose (FBG) level on the prognosis, clinical sequelae, and pulmonary absorption in hospitalized coronavirus... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 3240 |
| SubjectTerms | 1‐year mortality Absorption Blood Blood glucose clinical sequelae Cohort analysis Complications Confidence intervals coronavirus disease 2019 Coronaviruses COVID-19 Diabetes Diabetes mellitus Fasting fasting blood glucose Glucose Hospitalization Hyperglycemia Laboratory testing Medical prognosis Mortality nondiabetics Patients Prognosis Regression analysis Risk analysis Risk factors Statistical analysis Viral diseases Virology |
| Title | Effect of elevated fasting blood glucose level on the 1‐year mortality and sequelae in hospitalized COVID‐19 patients: A bidirectional cohort study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.27737 https://www.ncbi.nlm.nih.gov/pubmed/35357022 https://www.proquest.com/docview/2665558031 https://www.proquest.com/docview/2645859230 https://pubmed.ncbi.nlm.nih.gov/PMC9088618 |
| Volume | 94 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKD4gL39BAqQbEgUu2cezEMZyqQlUqFRCiVQ9Ike046sI2i7q7SPTET-DG_-OXMON8lKUgIW6RMnFiZ8Z-id-8Yeyx504Xlc5jVfs0lrZysVHKxILggcilNT6ofb7Kdw_k3lF2tMKe9bkwrT7E8MONIiPM1xTgxs42z0VDP5x8HqVKCcokJ64WAaK359JRhW53EHAmiHENynpVoSTdHK5cXosuAMyLPMlf8WtYgHausff9o7e8k4-jxdyO3Nlvqo7_2bfr7GoHTGGr9aQbbMU3N9nl_W7r_Rb73uocw7QGSklHiFpBbWbEmobAfoeO_Q4T4iHBtAHElsB_fP32BaMJTgLOR8wPpqkgMLgnxsO4geOudMn4DJvcfn348jlewzV0kq-zp7AFdtyuveHHJVBV39M5BGnc2-xg58W77d24q-oQOymFiq1Pcye4MEIL7pNCZsZp7VzieGpzUYnUZlmuJGEpU4usKoTjWteeKu4ZzcUdttpMG7_GQHmD-BNbMomXsqrQsbilVGJvLOJeE7En_fstXSd5TpU3JmUr1pyWONBlGOiIPRpMP7U6H38yWu-dpOxCfVYiwiHNNJwcI_ZwOI1BSjsvpvHTBdlI_CxDLJ1E7G7rU8NdRCYyhUgqYmrJ2wYDEgBfPtOMj4MQOHHUcl5gN4Mz_f3By739w3Bw799N77MrKaV6BGryOludny78AwRgc7vBLqXyzUaIt5_5gDHf |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB2VIgEXvj8CBQbEgUu2SezEMeJStVTb0i0Saqteqsh2HHVhm0XdXSR64idw4__xSxg72ZSlICFukTJO4mTGfrHfvAF4YWMj81JmoahsEnJdmlAJoULm4AHLuFbWq33uZv19vn2YHi7B63kuTKMP0S24ucjw47ULcLcgvXquGvrh5HMvEYKJS3DZVfR2yvkb78_Fo3LZ7CHQWBDSLJTOdYWiZLVrujgbXYCYF5mSvyJYPwVt3oCj-cM3zJOPvdlU98zZb7qO_9u7m3C9xaa41jjTLViy9W24Mmh33-_A90bqGMcVuqx0QqklVmriiNPoCfDYEuBx5KhIOK6R4CXGP75--0IBhSce6hPsR1WX6EncI2VxWONxW71keEaXXH93sLVBbWKJrerr5BWuoR42069fu0RX2Pd0il4d9y7sb77ZW--HbWGH0HDORKhtkhkWM8Uki22U81QZKY2JTJzojJUs0WmaCe7glKpYWubMxFJW1hXdUzJm92C5Htf2AaCwiiAoXUlFlvOyJN-KtcsmtkoT9FUBvJx_4MK0queu-MaoaPSak4JedOFfdADPO9NPjdTHn4xW5l5StNE-KQjkONk0Gh8DeNadpjh1my-qtuOZs-H0Z0ZwOgrgfuNU3V1YylJBYCoAseBunYHTAF88Uw-PvRa4o6llcU7d9N709wcvtgcH_uDhv5s-hav9vcFOsbO1-_YRXEtc5odnKq_A8vR0Zh8THpvqJz7sfgKxezUk |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwEB2VIlVcUPlsoMCAOHAJjWMnXsOpalm1hZYeaNVb5DiOumibrbrbSnDiJ3Dj__FLmHGygVVB4hbJYyfReOwnz_MbgJdeODOoTB7r2qexKisXW61tLBkeyFyV1ge1z4N850jtnWQnS_B2fhem1YfoD9w4MsJ6zQF-XtUbv0VDP59dvU61lvoG3ORkH_O5UnXYL8MD06YQaCmIaRPK5rJCSbrRd13cjK4hzOtEyT8BbNiBhqtwu4OOuNn6-g4s-eYurOx3yfF78KNVIsZJjXxpnEBkhbWdMq8ZAz8dO346jpkphJMGCf2h-Pnt-xea73gWkDihcrRNhYFjPbYeRw2edsVFRl9pyK2Px7vb1EcY7ERZp29wE8tRuzuGo0XkursXMwzitffhaPju09ZO3NVdiJ1SUselT3MnhbTSSOGTgcqsM8a5xIm0zGUl0zLLcq0Y7dhaZtVAOmFM7bkmnjVCPoDlZtL4NUDtLSFEGskmXqmqIteLki_7elsSMrURvJo7oHCdKDnXxhgXrZxyWpCviuCrCF70puetEsffjNbnXiy6YJwWhEFY1YyWrwie980URpwbsY2fXLINzaGM0G4SwcPW6f1bZCYzTVgnAr0wHXoDluhebGlGp0Gqm1lkuRjQb4aJ8-8PL_b2j8PDo_83fQYrh9vD4sPuwfvHcCvlexmBR7wOy7OLS_-E0NKsfBqi4hegRBOL |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+elevated+fasting+blood+glucose+level+on+the+1%E2%80%90year+mortality+and+sequelae+in+hospitalized+COVID%E2%80%9019+patients%3A+A+bidirectional+cohort+study&rft.jtitle=Journal+of+medical+virology&rft.au=Chai%2C+Chen&rft.au=Chen%2C+Kui&rft.au=Li%2C+Shoupeng&rft.au=Cheng%2C+Gang&rft.date=2022-07-01&rft.issn=0146-6615&rft.eissn=1096-9071&rft.volume=94&rft.issue=7&rft.spage=3240&rft.epage=3250&rft_id=info:doi/10.1002%2Fjmv.27737&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_jmv_27737 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon |